Portola Pharmaceuticals   Print Page    Close Window

To access The New England Journal of Medicine publication on the interim results from the ANNEXA-4 study of andexanet, visit: http://www.nejm.org/doi/full/10.1056/NEJMoa1607887 and NEJM ANNEXA-4 Supplement

Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
Q1 2017 Portola Pharmaceuticals, Inc. Financial Results Conference Call
Monday, May 8, 2017 1:30 p.m. PT

Portola Pharmaceuticals, Inc. at the Oppenheimer’s 27th Annual Healthcare Conference
Wednesday, March 22, 2017 1:35 p.m. ET
LocationNew York, NY

Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$38.65
Change (%) Stock is Up 0.20 (0.52%)
Volume419,677
Data as of 05/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. We are advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhib... More >>

Recent NewsMore >>
DateTitle 
05/18/17Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA)
SOUTH SAN FRANCISCO, Calif., May 18, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that preclinical and clinical data on cerdulatinib in relapsed/refractory b-cell malignancies will be presented at the European Hematology Association (EHA), which is taking place from June 22-25 in Madrid, Spain. Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancers. Cerdulati... 
Printer Friendly Version
05/09/17Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (ICML)
SOUTH SAN FRANCISCO, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that clinical results from the Phase 2 study of cerdulatinib in patients with relapsed/refractory b-cell malignancies will be shared in an oral presentation at the International Conference on Malignant Lymphoma (ICML), which is taking place from June 14-17 in Lugano, Switzerland.  Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to tr... 
Printer Friendly Version
05/08/17Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today reported financial results and provided a corporate update for the quarter ended March 31, 2017. “During the first quarter of 2017 we continued to focus on regulatory activities for betrixaban and AndexXa™. Our goal is to gain approval for both products this year in the United States and in 2018 in the European Union,” said Bill Lis, chief executive officer of Portola. “Both are hig... 
Printer Friendly Version
05/01/17Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Monday, May 8
SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2017, and provide a general business overview on Monday, May 8, 2017 at 4:30 p.m. ET (1:30 p.m. PT). Conference Call Details The live conference call on Monday, May 8, 2017, at 4:30 p.m. Eastern Time, can be accessed by phone by calling (844) 452-... 
Printer Friendly Version
03/07/17Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17
SOUTH SAN FRANCISCO, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that new data from the pivotal Phase 3 APEX Study of the Company’s investigational drug betrixaban will be presented in a poster session at the upcoming American College of Cardiology’s (ACC) 66th Annual Scientific Session & Expo, which is taking place from March 17-19 at the Walter E. Washington Convention Center in Washington, D.C. Additionally, clinical data on bet... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.